Inovio Pharmaceuticals Securities Class Action
Analysis based on 6 articles · First reported Feb 14, 2026 · Last updated Mar 18, 2026
The market is impacted by the potential financial liabilities for Rhythm Pharmaceuticals due to the class action lawsuit, which could lead to further stock price volatility. The rejection of accelerated approval for INO-3107 by the United States — Food and Drug Administration has already caused a significant drop in Rhythm Pharmaceuticals' stock, signaling investor concern over its regulatory and commercial prospects.
Faruqi & Faruqi, a national securities law firm, is investigating Rhythm Pharmaceuticals and reminding investors of the April 7, 2026 deadline to seek lead plaintiff in a federal securities class action. The lawsuit alleges that Rhythm Pharmaceuticals and its executives made false and misleading statements regarding the deficient manufacturing of its CELLECTRA device and the overstated regulatory and commercial prospects of its INO-3107 treatment. This follows the United States — Food and Drug Administration's decision on December 29, 2025, to accept Rhythm Pharmaceuticals' Biologics License Application for INO-3107 on a standard review timeline, stating that the company did not submit adequate information for accelerated approval. This news caused Rhythm Pharmaceuticals' stock price to fall by 24.45%.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard